Holen Sie sich die Stockscreener-App
5.485
6.65%
-0.395
Schlusskurs vom Vortag:
$5.88
Offen:
$5.85
24-Stunden-Volumen:
65,968
Relative Volume:
1.65
Marktkapitalisierung:
$31.22M
Einnahmen:
$147.75M
Nettoeinkommen (Verlust:
$-284.23M
KGV:
-1.872
EPS:
-2.93
Netto-Cashflow:
$-317.54M
1W Leistung:
-28.94%
1M Leistung:
-28.25%
6M Leistung:
-35.89%
1J Leistung:
-78.68%
1-Tages-Spanne:
$5.47
$6.0199
1-Wochen-Bereich:
$5.47
$7.875
52-Wochen-Spanne:
$4.50
$38.25
Fibrogen Inc Stock (FGEN) Company Profile
Firmenname
Fibrogen Inc
Sektor
Branche
Telefon
415-978-1200
Adresse
350 BAY STREET, SAN FRANCISCO, CA
Vergleichen Sie FGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
5.4801 | 31.22M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.06 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.31 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.82 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.44 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-26 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2023-06-26 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Hochstufung | Stifel | Hold → Buy |
| 2023-01-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-09-22 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-07-16 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-03-31 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-03-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-26 | Eingeleitet | Raymond James | Underperform |
| 2020-07-10 | Fortgesetzt | Stifel | Buy |
| 2020-05-01 | Eingeleitet | Cowen | Market Perform |
| 2020-04-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-05-29 | Fortgesetzt | Goldman | Neutral |
| 2019-05-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-02-11 | Fortgesetzt | Stifel | Buy |
| 2018-12-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2017-08-08 | Bestätigt | Leerink Partners | Outperform |
| 2017-08-08 | Bestätigt | Stifel | Buy |
| 2017-07-21 | Herabstufung | Goldman | Buy → Neutral |
| 2017-07-11 | Eingeleitet | Jefferies | Buy |
| 2016-02-11 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
| 2015-12-04 | Eingeleitet | Citigroup | Buy |
| 2015-09-23 | Eingeleitet | Lake Street | Hold |
| 2015-07-29 | Eingeleitet | Citigroup | Buy |
| 2015-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2014-12-09 | Eingeleitet | Stifel | Buy |
Alle ansehen
Fibrogen Inc Aktie (FGEN) Neueste Nachrichten
FibroGen (FGEN) Trading Halted Pending News Release | FGEN Stock News - GuruFocus
FibroGen Enters New Agreement with HiFiBiO - TipRanks
Fibrogen IncOn June 12 Enters Termination, Asset Transfer And License Agreement With Hifibio - marketscreener.com
FibroGen (FGEN) Announces 1-for-25 Reverse Stock Split | FGEN St - GuruFocus
FibroGen to implement 1-for-25 reverse stock split; shares down 15% - MSN
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Adobe, RH And 3 Stocks To Watch Heading Into FridayAdobe (NASDAQ:ADBE), FibroGen (NASDAQ:FGEN) - Benzinga
FibroGen Announces 1-for-25 Reverse Stock Split | FGEN Stock New - GuruFocus
FibroGen Announces Reverse Stock Split Effective June 16 - TipRanks
FibroGen to Implement 1-for-25 Reverse Stock Split - marketscreener.com
FibroGen To Implement 1-for-25 Reverse Stock Split - Nasdaq
FibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025 - Nasdaq
Fibrogen Announces 1-For-25 Reverse Stock Split - marketscreener.com
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen's Massive 1-for-25 Reverse Split Cuts 101M Shares to 4MWhat Investors Must Know - Stock Titan
Millennium Management LLC Lowers Stock Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen expands board with biotech veteran Kauffman By Investing.com - Investing.com South Africa
FibroGen expands board with biotech veteran Kauffman - Investing.com Australia
FibroGen Amends Financing Agreement for Flexibility - TipRanks
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors | FGEN Stock News - GuruFocus
Fibrogen Appoints Michael Kauffman To Its Board Of Directors - marketscreener.com
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - GlobeNewswire
FibroGen Strengthens Board with Velcade Developer: Key Move for Pipeline Advancement - Stock Titan
Squarepoint Ops LLC Takes Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Two Sigma Advisers LP Has $465,000 Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen, Inc. (NASDAQ:FGEN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World
FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline - MSN
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline By Investing.com - Investing.com South Africa
FibroGen First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline - Investing.com Australia
HC Wainwright Has Negative Outlook for FibroGen Q2 Earnings - Defense World
FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes - TipRanks
FibroGen (NASDAQ:FGEN) Earns Buy Rating from HC Wainwright - Defense World
FibroGen (FGEN) Boosts Sale Proceeds from Chinese Division - GuruFocus
FibroGen (FGEN) Receives Reaffirmed Buy Rating from HC Wainwrigh - GuruFocus
FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
FibroGen Inc earnings beat by $0.15, revenue fell short of estimates - Investing.com UK
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ... - Yahoo Finance
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid Revenue Decline - GuruFocus
FibroGen Reports Q1 2025 Earnings and Strategic Updates - TipRanks
Earnings call transcript: FibroGen Q1 2025 sees revenue drop, stock rises - Investing.com Canada
FibroGen Q1 2025 Earnings Call Transcript - MarketBeat
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
FibroGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimates at $2.7M, EPS Misses with $0.16 Loss - GuruFocus
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
FibroGen: Q1 Earnings Snapshot - San Antonio Express-News
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
FIBROGEN INC SEC 10-Q Report - TradingView
Finanzdaten der Fibrogen Inc-Aktie (FGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fibrogen Inc-Aktie (FGEN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
1.59%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):